These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24499953)

  • 1. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.
    Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D;
    AIDS; 2014 May; 28(8):1155-60. PubMed ID: 24499953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of spontaneous clearance of hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort.
    Clausen LN; Weis N; Schønning K; Fenger M; Krarup H; Bukh J; Benfield T
    Scand J Infect Dis; 2011 Oct; 43(10):798-803. PubMed ID: 21728744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.
    Bani-Sadr F; Carrat F; Bedossa P; Piroth L; Cacoub P; Perronne C; Degott C; Pol S;
    AIDS; 2006 Feb; 20(4):525-31. PubMed ID: 16470116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.
    Grint D; Peters L; Reekie J; Soriano V; Kirk O; Knysz B; Suetnov O; Lazzarin A; Ledergerber B; Rockstroh JK; Mocroft A;
    HIV Med; 2013 Jul; 14(6):370-8. PubMed ID: 23534815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
    Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
    J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.
    Saadoun D; Aaron L; Resche-Rigon M; Pialoux G; Piette JC; Cacoub P;
    AIDS; 2006 Apr; 20(6):871-7. PubMed ID: 16549971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
    Mijch A; Sasadeusz J; Hellard M; Dunne M; McCaw R; Bowden S; Gowans EJ
    Antivir Ther; 2005; 10(2):277-84. PubMed ID: 15865222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.
    Martinez V; Ta TD; Mokhtari Z; Guiguet M; Miailhes P; Valantin MA; Charlotte F; Bertheau P; Molina JM; Katlama C; Caumes E
    BMC Res Notes; 2012 Jul; 5():180. PubMed ID: 22490728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.